Aurore Pire, Theo Z Hirsch, Guillaume Morcrette, Sandrine Imbeaud, Barkha Gupta, Jill Pilet, Marianna Cornet, Monique Fabre, Catherine Guettier, Sophie Branchereau, Laurence Brugières, Florent Guerin, Véronique Laithier, Carole Coze, Genta Nagae, Eiso Hiyama, Pierre Laurent-Puig, Sandra Rebouissou, Sabine Sarnacki, Christophe Chardot, Carmen Capito, Cécile Faure-Conter, Isabelle Aerts, Sophie Taque, Brice Fresneau, Jessica Zucman-Rossi
BACKGROUND: Hepatoblastoma is the most frequent pediatric liver cancer. The current treatments lead to 80% of survival rate at 5 years. In this study, we evaluated the clinical relevance of molecular features to identify patients at risk of chemoresistance, relapse and death of disease. METHODS: All the clinical data of 86 children with hepatoblastoma were retrospectively collected. Pathological slides were reviewed, tumor DNA sequencing (by whole exome, whole genome or target) and transcriptomic profiling with RNAseq or 300-genes panel were performed...
February 1, 2024: European Journal of Cancer